Effect of verification imaging on in vivo dosimetry results using Gafchromic EBT3 film |
| |
| Affiliation: | 1. Icon Integrated Cancer Care, 9 MeLennan Court, North Lakes, Qld 4509, Australia.;2. Genesis Cancer Care, Wesley Medical Centre, Suite 1, 40 Chasely St, Auchenflower, Qld 4066, Australia;3. School of Chemistry, Physics, and Mechanical Engineering, Queensland University of Technology, GPO Box 2434, Brisbane, Qld 4000, Australia;4. Epworth Radiation Oncology, 32 Erin Street, Richmond, Vic 3121, Australia;1. Winship Cancer Institute of Emory University, Atlanta, Georgia;2. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;1. Department of Radiology, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan;2. Brain & Mind Research Center, Nagoya University, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya, Aichi, Japan;3. Nagoya University, 1-1-20 Daiko-Minami, Higashi-ku, Nagoya, Aichi, Japan;4. Faculty of Radiological Technology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan;5. Central Block of Radiology, Nagoya University Hospital, 65 Tsurumai-cho, Shouwa-ku, Nagoya, Aichi, Japan;1. MD Anderson Cancer Center at Cooper, Camden, New Jersey;2. University of Texas, MD Anderson Cancer Center, Houston, Texas;3. MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Houston, Texas;1. Department of Medical Physics and Biomedical Engineering, University College London, London, UK;2. Research Complex at Harwell, Oxford Harwell Campus, Didcot, UK;3. Institute for Clinical Radiology, Ludwig-Maximilians-University, Munich, Germany;4. Department of Physics, Ludwig-Maximilians-University, Garching, Germany;5. European Synchrotron Radiation Facility, Grenoble, France;6. Diamond Light Source, Harwell Oxford Campus, Didcot, UK;7. London Centre for Nanotechnology, London, UK;1. GSI Helmholtz Centre for Heavy Ion Research, Planckstr. 1, 64291 Darmstadt, Germany;2. Champalimaud Centre for the Unknown, Av. Brasília, 1400-038 Lisbon, Portugal |
| |
| Abstract: | In this work, the apparent treatment dose that kV planar or CBCT imaging contributes to Gafchromic EBT3 film used for in vivo dosimetry, was investigated. Gafchromic EBT3 film pieces were attached to a variety of phantoms and irradiated using the linear accelerator’s built-in kV imaging system, in both kV planar mode and CBCT mode. To evaluate the sensitivity of the film in the clinical scenario where dose contributions are received from both imaging and treatment, additional pieces of film were irradiated using base doses of 50 cGy and then irradiated using selected kV planar and CBCT techniques. For kV planar imaging, apparent treatment doses of up to 3.4 cGy per image pair were seen. For CBCT, apparent treatment doses ranged from 0.22 cGy to 3.78 cGy. These apparent doses were reproducible with and without the inclusion of the 50 cGy base dose. The contribution of apparent treatment dose from both planar kV as well as CBCT imaging can be detected, even in conjunction with an actual treatment dose. The magnitude of the apparent dose was found to be dependent on patient geometry, scanning protocol, and measurement location. It was found that the apparent treatment dose from the imaging could add up to 8% of additional uncertainty to the in vivo dosimetry result, if not taken into account. It is possible for this apparent treatment dose to be accounted for by subtraction of the experimentally determined apparent doses from in vivo measurements, as demonstrated in this work. |
| |
| Keywords: | Gafchromic In vivo Dosimetry Imaging EBT3 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
